CVS Health Corp (CVS)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $114.32B
Last updated: Nov 17, 2026 at 11:04 AM ET
CVS Health Corp (CVS) Financials: Revenue, Profit and Cash Flow
CVS Health reported revenue of $402.07B for the fiscal year ended Dec 31, 2025, up 7.8% from the year before. That year, net income was $1.73B with a net margin of 0.4%, operating cash flow was $10.64B and free cash flow was $7.81B. The quarter ended Sep 30, 2026 had revenue of $108.40B and net income of $2.17B.
Revenue and Margins
The operating margin was 1.2% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $177.55B, a compound annual rate of 9.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $402.07B | +7.8% | 45.0% | 1.2% | 0.4% |
| Dec 2024 | $372.81B | +4.2% | 44.7% | 2.3% | 1.2% |
| Dec 2023 | $357.78B | +10.9% | 39.3% | 3.8% | 2.3% |
| Dec 2022 | $322.47B | +10.4% | 38.9% | 2.5% | 1.3% |
| Dec 2021 | $292.11B | +8.7% | 17.8% | 4.6% | 2.7% |
| Dec 2020 | $268.71B | +4.6% | 18.3% | 5.2% | 2.7% |
| Dec 2019 | $256.78B | +32.0% | 17.7% | 4.7% | 2.6% |
| Dec 2018 | $194.58B | +5.3% | 16.2% | 2.1% | -0.3% |
| Dec 2017 | $184.79B | +4.1% | 15.4% | 5.2% | 3.6% |
| Dec 2016 | $177.55B | N/A | 17.5% | 5.8% | 3.0% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 62.3% from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B | $268.71B | $256.78B | $194.58B | $184.79B | $177.55B |
| Cost of revenue | $221.17B | $206.29B | $217.10B | $196.89B | $239.99B | $219.66B | $211.25B | $163.04B | $156.26B | $146.53B |
| Gross profit | $180.90B | $166.52B | $140.68B | $125.58B | $52.12B | $49.05B | $45.53B | $31.54B | $28.53B | $31.01B |
| Operating income | $4.66B | $8.52B | $13.74B | $7.95B | $13.31B | $13.91B | $11.99B | $4.02B | $9.54B | $10.39B |
| Net income | $1.73B | $4.59B | $8.37B | $4.33B | $7.99B | $7.19B | $6.63B | -$596.00M | $6.62B | $5.32B |
| EBITDA | $9.38B | $13.21B | $18.20B | $12.35B | $17.98B | $18.56B | $16.48B | $6.74B | $11.81B | $12.83B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.40B | $106.10B | $100.43B | $105.69B | $102.87B | $98.92B | $94.59B | $97.71B | $95.43B | $91.23B | $88.44B | $93.81B |
| Gross profit | $47.21B | $47.23B | $44.98B | $46.63B | $45.83B | $44.91B | $43.53B | $42.44B | $42.48B | $41.24B | $40.36B | $56.84B |
| Operating income | $3.57B | $4.70B | $4.68B | $2.11B | -$3.21B | $2.38B | $3.37B | $2.37B | $832.00M | $3.04B | $2.27B | $3.37B |
| Net income | $2.17B | $3.00B | $2.96B | $2.92B | -$3.99B | $1.01B | $1.78B | $1.62B | $71.00M | $1.77B | $1.12B | $2.05B |
Balance Sheet
As of Dec 2025, total debt of $64.57B exceeded cash and equivalents by $56.12B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $253.54B | $253.22B | $249.73B | $228.28B | $233.00B | $230.72B | $222.45B | $196.46B | $95.13B | $94.46B |
| Current assets | $74.71B | $68.64B | $67.86B | $65.63B | $60.01B | $56.37B | $50.30B | $45.24B | $31.23B | $31.04B |
| Cash and equivalents | $8.45B | $8.59B | $8.20B | $12.95B | $9.41B | $7.85B | $5.68B | $4.06B | $1.70B | $3.37B |
| Total liabilities | $178.16B | $177.49B | $173.09B | $156.51B | $157.62B | $161.01B | $158.28B | $137.91B | $57.44B | $57.63B |
| Short-term debt | $4.07B | $5.74B | $2.97B | $1.78B | $4.21B | $5.44B | $3.78B | $1.99B | $4.82B | $1.92B |
| Long-term debt | $60.50B | $60.53B | $58.64B | $50.48B | $51.97B | $59.21B | $64.70B | $71.44B | $22.18B | $25.61B |
| Shareholder equity | $75.21B | $75.56B | $76.46B | $71.47B | $75.08B | $69.39B | $63.86B | $58.23B | $37.69B | $36.83B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $258.07B | $253.77B | $252.97B | $261.06B | $255.33B | $258.34B | $255.59B | $253.22B | $252.43B | $252.48B | $249.74B | $249.73B |
| Total liabilities | $177.39B | $173.87B | $175.34B | $185.68B | $182.22B | $180.79B | $178.47B | $177.49B | $177.32B | $177.37B | $175.59B | $173.09B |
| Cash and equivalents | $11.74B | $11.33B | $9.54B | $8.51B | $9.10B | $11.79B | $10.08B | $8.59B | $6.88B | $12.51B | $9.80B | $8.20B |
| Shareholder equity | $80.50B | $79.70B | $77.46B | $75.21B | $72.93B | $77.38B | $76.93B | $75.56B | $74.94B | $74.93B | $73.97B | $76.46B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 73.4% of operating cash flow. Dividends came to 43.5% of it, with no share repurchases.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.64B | $9.11B | $13.43B | $16.18B | $18.27B | $15.87B | $12.85B | $8.87B | $8.01B | $10.14B |
| Capital expenditures | $2.83B | $2.78B | $3.03B | $2.73B | $2.52B | $2.44B | $2.46B | $2.04B | $1.92B | $2.22B |
| Free cash flow | $7.81B | $6.33B | $10.39B | $13.45B | $15.74B | $13.43B | $10.39B | $6.83B | $6.09B | $7.92B |
| Dividends paid | $3.40B | $3.37B | $3.13B | $2.91B | $2.63B | $2.62B | $2.60B | $2.04B | $2.05B | $1.88B |
| Share repurchases | $0 | $3.02B | $2.01B | $3.50B | $0 | $0 | N/A | N/A | $4.36B | $4.46B |
| Investing cash flow | -$5.87B | -$7.61B | -$20.89B | -$5.05B | -$5.26B | -$5.53B | -$3.34B | -$43.28B | -$2.88B | -$2.47B |
| Financing cash flow | -$4.94B | -$1.14B | $2.68B | -$10.52B | -$11.36B | -$7.70B | -$7.65B | $36.82B | -$6.75B | -$6.76B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.72B | $6.34B | $4.25B | $3.39B | $796.00M | $1.90B | $4.56B | $1.86B | -$745.00M | $3.09B | $4.90B | -$2.64B |
| Capital expenditures | $817.00M | $691.00M | $849.00M | $784.00M | $698.00M | $607.00M | $743.00M | $768.00M | $670.00M | $638.00M | $705.00M | $911.00M |
| Free cash flow | $3.91B | $5.65B | $3.40B | $2.61B | $98.00M | $1.29B | $3.81B | $1.09B | -$1.42B | $2.45B | $4.20B | -$3.55B |
Frequently Asked Questions About CVS
What is CVS Health's annual revenue?
CVS Health reported revenue of $402.07B for the fiscal year ended Dec 31, 2025.
How fast is CVS Health's revenue growing?
Revenue was up 7.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 7.6%.
Is CVS Health profitable?
Yes. CVS Health reported net income of $1.73B for the fiscal year ended Dec 31, 2025, with a net margin of 0.4%.
How much free cash flow does CVS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $10.64B minus capital expenditures of $2.83B produced free cash flow of $7.81B.
How much debt does CVS Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $60.50B, short-term debt of $4.07B and cash and equivalents of $8.45B.
CVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts